NCT00842075View on ClinicalTrials.gov

Pramlintide in Adolescents With Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Type 1 Diabetes
Interventions
DRUG

pramlintide

subcutaneous injection (15 mcg initial dose)prior to meals

Trial Locations (1)

80010

Barbara Davis Center, Aurora

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University of Colorado, Denver

OTHER